
RNA Interference New Drug Developer
Disclaimer: Due to limited proficiency, errors are inevitable, and some information may not be the most up-to-date. Feel free to point out in the comments. This article is only an introduction to medical and health-related drugs, not a recommendation of treatment plans (if involved); this article does not constitute any investment advice.
June 3, SirnaomicsAnnounce that the following matters will take effect from May 31, 2024: (i) Due toDr. Francois LebelPlans to devote more time to handling other affairs, he hasResignation from the Position of Chief Medical Officer of the GroupDr. Lebel has agreed to serve as the head of the group's pharmaceuticals.Senior Advisor for Development Strategy Affairs。The Company will seek to identify a suitable candidate to fill the vacancy of Chief Medical Officer. During this transition period, the Group will engage a contract research organization to perform its clinical development functions; and (ii) due toMr. Ye YongjiPlans to devote more time to handling other affairs, he hasResignation as Chief Financial Officer of the GroupOne position. Mr. Ye will continue to serve as an advisor to the Group on corporate transaction-related matters. The Board is satisfied that, following Mr. Ye's resignation, the Company has sufficient resources to carry out its strategic planning, financial management analysis, and internal control functions.

The company has a rich R&D pipeline, with indications covering tumors, medical aesthetics, antiviral treatments, and cardiovascular diseases, demonstrating significant differentiation.Sirnaomics is advancing its priority product pipeline and conducting clinical trials for its lead candidates, STP705 and STP707, in the United States.Sirnaomics is conducting five siRNA clinical trials with STP122G. In addition, RV-1730 and RV-1770, the mRNA vaccine projects led by its non-wholly owned subsidiary RNAimmune, have received FDA approval for Investigational New Drug (IND) applications in the United States.
R&D Pipeline

Reference: Company Announcement